US PTO voids Seagen’s ADC patent infringement claims against Daiichi
The decision invalidates all claims of patent infringement, which has been central in litigation of breast cancer drug Enhertu.
The decision invalidates all claims of patent infringement, which has been central in litigation of breast cancer drug Enhertu.
What's Your Reaction?
